Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

– Permanent, product-specific J-code facilitates efficient claims and reimbursement –

OMER : 13.44 (+7.18%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 13.44 (+7.18%)
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET

OMER : 13.44 (+7.18%)
Omeros Burns Cash While Everyone Waits for YARTEMLEA's Story

Barchart Research What to Expect from OMER Earnings OMER Generated March 30, 2026 Current Price $9.81 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Burns Cash While Everyone...

OMER : 13.44 (+7.18%)
Omeros Has Been Quietly Burning Through Cash. This Week, the Story Either Changes or It Doesn't.

Barchart Research What to Expect from OMER Earnings OMER Generated March 27, 2026 Current Price $9.88 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Has Been Quietly Burning...

OMER : 13.44 (+7.18%)
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros...

OMER : 13.44 (+7.18%)
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52 nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on...

OMER : 13.44 (+7.18%)
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients —

OMER : 13.44 (+7.18%)
Omeros Announces First Commercial Sales of YARTEMLEA®

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA —

OMER : 13.44 (+7.18%)
Omeros Announces New Date for YARTEMLEA® Approval Conference Call

— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET —

OMER : 13.44 (+7.18%)

Barchart Exclusives

Only 3 Dividend Kings Passed This Brutal Screen. They Could Pay You Well for Years to Come.
Three Dividend Kings with 50+ years of raises combine reliable income, solid growth, and analyst support, making them stand out in a shaky market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.